139 related articles for article (PubMed ID: 1697314)
1. Marked difference in the in vivo antitumor efficacy between two immunotoxins targeted to different epitopes of common acute lymphoblastic leukemia antigen (CD10). Mechanisms involved in the differential activities of immunotoxins.
Luo Y; Seon BK
J Immunol; 1990 Sep; 145(6):1974-82. PubMed ID: 1697314
[TBL] [Abstract][Full Text] [Related]
2. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
Hara H; Luo Y; Haruta Y; Seon BK
Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
[TBL] [Abstract][Full Text] [Related]
3. Unique epitopes of common acute lymphoblastic leukemia antigen detected by new monoclonal antibodies.
Matsuzaki H; Haruta Y; Fukukawa T; Barcos MP; Seon BK
Cancer Res; 1987 Apr; 47(8):2160-6. PubMed ID: 2435407
[TBL] [Abstract][Full Text] [Related]
4. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
Yokota S; Hara H; Luo Y; Seon BK
Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557
[TBL] [Abstract][Full Text] [Related]
5. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated IgD on murine B cells.
May RD; Finkelman FD; Wheeler HT; Uhr JW; Vitetta ES
J Immunol; 1990 May; 144(9):3637-42. PubMed ID: 1691764
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
[TBL] [Abstract][Full Text] [Related]
8. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
Raso V; Ritz J; Basala M; Schlossman SF
Cancer Res; 1982 Feb; 42(2):457-64. PubMed ID: 6948605
[TBL] [Abstract][Full Text] [Related]
10. [Characterization of murine monoclonal antibodies against the common acute leukemia antigen (CALLA)].
Seifert M; Eichler W; Fiebig H
Allerg Immunol (Leipz); 1990; 36(4):267-76. PubMed ID: 2151502
[TBL] [Abstract][Full Text] [Related]
11. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
12. Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo.
Rostaing-Capaillon O; Casellas P
Cancer Res; 1990 May; 50(10):2909-16. PubMed ID: 1692250
[TBL] [Abstract][Full Text] [Related]
13. Establishment of ascitic tumor of human pre-B acute lymphoblastic leukemia in nonconditioned nude mice.
Luo Y; Hara H; Haruta Y; Seon BK
Cancer Res; 1989 Feb; 49(3):706-10. PubMed ID: 2783384
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.
Biddle WC; Haruta Y; Seon BK; Henderson ES; Sarcione EJ
Leuk Res; 1989; 13(8):699-707. PubMed ID: 2529399
[TBL] [Abstract][Full Text] [Related]
15. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells.
Press OW; Martin PJ; Thorpe PE; Vitetta ES
J Immunol; 1988 Dec; 141(12):4410-7. PubMed ID: 2461993
[TBL] [Abstract][Full Text] [Related]
16. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
17. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins.
Manske JM; Buchsbaum DJ; Vallera DA
J Immunol; 1989 Mar; 142(5):1755-66. PubMed ID: 2465347
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
19. Expression of a 33-kDa antigen Tm 1 on lymphocyte surface after modulation of cell surface antigens by IgM monoclonal antibody.
Hara T; Jung LK; Fu SM
J Immunol; 1988 Feb; 140(4):1028-33. PubMed ID: 2963858
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
